uniQure N.V. (QURE)
NASDAQ: QURE · Real-Time Price · USD
7.45
+0.86 (13.05%)
At close: Dec 6, 2024, 4:00 PM
7.40
-0.05 (-0.67%)
After-hours: Dec 6, 2024, 5:22 PM EST

Company Description

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases.

It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B.

The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington’s disease.

In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer’s disease; and AMT-210 that is in preclinical trial to treat Parkinson’s disease.

The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

uniQure N.V.
uniQure logo
Country Netherlands
Founded 1998
IPO Date Jun 20, 2007
Industry Biotechnology
Sector Healthcare
Employees 480
CEO Matthew Kapusta

Contact Details

Address:
Paasheuvelweg 25
Amsterdam, 1105 BP
Netherlands
Phone 31 20 240 6000
Website uniqure.com

Stock Details

Ticker Symbol QURE
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001590560
CUSIP Number N90064101
ISIN Number NL0010696654
SIC Code 2834

Key Executives

Name Position
Christian Klemt Chief Financial Officer, Principal Financial Officer and GM of Amsterdam Site
Richard Porter Ph.D. Chief Business and Scientific Officer
Dr. Jeannette Potts J.D., Ph.D. Chief Legal and Compliance Officer and Corporate Secretary
Prof. Hugo Katus Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany
Dr. Amin Abujoub Ph.D. Chief Technical Operations
Dr. Tamara Tugal Ph.D., MBA Business Development Director
Erin Boyer Chief People and Culture Officer
Dr. Walid Abi-Saab M.D. Chief Medical Officer
Eileen Sawyer Vice President of Global Medical Affairs

Latest SEC Filings

Date Type Title
Nov 21, 2024 8-K Current Report
Nov 14, 2024 SCHEDULE 13G/A Filing
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 5, 2024 10-Q Quarterly Report
Nov 5, 2024 8-K Current Report
Oct 25, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Oct 18, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Oct 15, 2024 8-K Current Report
Sep 23, 2024 8-K Current Report